BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Religare maintains hold on Torrent Pharma
Torrent Pharma reported an operationally in-line Q4. Management expects R&D costs to scale up to 8 per cent in FY17 from 4 per cent currently. We believe Torrent Pharma's US business, which contributed 40 per cent of FY16 revenues will continue to face growth challenges.